Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

Giulia Fulci, Laura Breymann, Davide Gianni, Kazuhiko Kurozumi, Sarah S. Rhee, Jianhua Yu, Balveen Kaur, David N. Louis, Ralph Weissleder, Michael A. Caligiuri, E. Antonio Chiocca

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer. We have shown that animals that have brain tumors and are treated with a herpes simplex virus (HSV)-derived OV live significantly longer when cyclophosphamide (CPA) is preadministered. Here, we explore the mechanisms behind this finding. In a syngeneic rat glioma model, intratumoral HSV administration is associated with rapid increase of natural killer cells, microglia/macrophages (CD68+ and CD163+), and IFN-γ. Pretreatment with CPA enhances HSV replication and oncolysis and reduces an HSV-mediated increase in CD68+ and CD163+ cells and intratumoral IFN-γ. Molecular imaging shows CPA pretreatment to inhibit HSV-induced infiltration of tumor-associated phagocytic cells. Our results reveal molecular and cellular mechanisms that inhibit intratumoral spread of HSV and suggest a therapeutic path for improving the efficacy of virotherapy as a treatment for cancer.

Original languageEnglish
Pages (from-to)12873-12878
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number34
DOIs
Publication statusPublished - Aug 22 2006
Externally publishedYes

Fingerprint

Simplexvirus
Innate Immunity
Glioma
Cyclophosphamide
Oncolytic Virotherapy
Oncolytic Viruses
Neoplasms
Molecular Imaging
Microglia
Phagocytes
Virus Replication
Brain Neoplasms
Natural Killer Cells
Macrophages
Clinical Trials
Therapeutics

Keywords

  • Brain tumor
  • Gene therapy
  • Herpes simplex virus
  • Innate immunity
  • Oncolytic virus

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. / Fulci, Giulia; Breymann, Laura; Gianni, Davide; Kurozumi, Kazuhiko; Rhee, Sarah S.; Yu, Jianhua; Kaur, Balveen; Louis, David N.; Weissleder, Ralph; Caligiuri, Michael A.; Chiocca, E. Antonio.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 34, 22.08.2006, p. 12873-12878.

Research output: Contribution to journalArticle

Fulci, G, Breymann, L, Gianni, D, Kurozumi, K, Rhee, SS, Yu, J, Kaur, B, Louis, DN, Weissleder, R, Caligiuri, MA & Chiocca, EA 2006, 'Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses', Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 34, pp. 12873-12878. https://doi.org/10.1073/pnas.0605496103
Fulci, Giulia ; Breymann, Laura ; Gianni, Davide ; Kurozumi, Kazuhiko ; Rhee, Sarah S. ; Yu, Jianhua ; Kaur, Balveen ; Louis, David N. ; Weissleder, Ralph ; Caligiuri, Michael A. ; Chiocca, E. Antonio. / Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 34. pp. 12873-12878.
@article{a71599c1005e4b979fc59fcad74bd4f9,
title = "Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses",
abstract = "Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer. We have shown that animals that have brain tumors and are treated with a herpes simplex virus (HSV)-derived OV live significantly longer when cyclophosphamide (CPA) is preadministered. Here, we explore the mechanisms behind this finding. In a syngeneic rat glioma model, intratumoral HSV administration is associated with rapid increase of natural killer cells, microglia/macrophages (CD68+ and CD163+), and IFN-γ. Pretreatment with CPA enhances HSV replication and oncolysis and reduces an HSV-mediated increase in CD68+ and CD163+ cells and intratumoral IFN-γ. Molecular imaging shows CPA pretreatment to inhibit HSV-induced infiltration of tumor-associated phagocytic cells. Our results reveal molecular and cellular mechanisms that inhibit intratumoral spread of HSV and suggest a therapeutic path for improving the efficacy of virotherapy as a treatment for cancer.",
keywords = "Brain tumor, Gene therapy, Herpes simplex virus, Innate immunity, Oncolytic virus",
author = "Giulia Fulci and Laura Breymann and Davide Gianni and Kazuhiko Kurozumi and Rhee, {Sarah S.} and Jianhua Yu and Balveen Kaur and Louis, {David N.} and Ralph Weissleder and Caligiuri, {Michael A.} and Chiocca, {E. Antonio}",
year = "2006",
month = "8",
day = "22",
doi = "10.1073/pnas.0605496103",
language = "English",
volume = "103",
pages = "12873--12878",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "34",

}

TY - JOUR

T1 - Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

AU - Fulci, Giulia

AU - Breymann, Laura

AU - Gianni, Davide

AU - Kurozumi, Kazuhiko

AU - Rhee, Sarah S.

AU - Yu, Jianhua

AU - Kaur, Balveen

AU - Louis, David N.

AU - Weissleder, Ralph

AU - Caligiuri, Michael A.

AU - Chiocca, E. Antonio

PY - 2006/8/22

Y1 - 2006/8/22

N2 - Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer. We have shown that animals that have brain tumors and are treated with a herpes simplex virus (HSV)-derived OV live significantly longer when cyclophosphamide (CPA) is preadministered. Here, we explore the mechanisms behind this finding. In a syngeneic rat glioma model, intratumoral HSV administration is associated with rapid increase of natural killer cells, microglia/macrophages (CD68+ and CD163+), and IFN-γ. Pretreatment with CPA enhances HSV replication and oncolysis and reduces an HSV-mediated increase in CD68+ and CD163+ cells and intratumoral IFN-γ. Molecular imaging shows CPA pretreatment to inhibit HSV-induced infiltration of tumor-associated phagocytic cells. Our results reveal molecular and cellular mechanisms that inhibit intratumoral spread of HSV and suggest a therapeutic path for improving the efficacy of virotherapy as a treatment for cancer.

AB - Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer. We have shown that animals that have brain tumors and are treated with a herpes simplex virus (HSV)-derived OV live significantly longer when cyclophosphamide (CPA) is preadministered. Here, we explore the mechanisms behind this finding. In a syngeneic rat glioma model, intratumoral HSV administration is associated with rapid increase of natural killer cells, microglia/macrophages (CD68+ and CD163+), and IFN-γ. Pretreatment with CPA enhances HSV replication and oncolysis and reduces an HSV-mediated increase in CD68+ and CD163+ cells and intratumoral IFN-γ. Molecular imaging shows CPA pretreatment to inhibit HSV-induced infiltration of tumor-associated phagocytic cells. Our results reveal molecular and cellular mechanisms that inhibit intratumoral spread of HSV and suggest a therapeutic path for improving the efficacy of virotherapy as a treatment for cancer.

KW - Brain tumor

KW - Gene therapy

KW - Herpes simplex virus

KW - Innate immunity

KW - Oncolytic virus

UR - http://www.scopus.com/inward/record.url?scp=33748088164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748088164&partnerID=8YFLogxK

U2 - 10.1073/pnas.0605496103

DO - 10.1073/pnas.0605496103

M3 - Article

VL - 103

SP - 12873

EP - 12878

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 34

ER -